Trial Profile
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment 1% in Subjects With Actinic Keratosis on the Face or Scalp
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2021
Price :
$35
*
At a glance
- Drugs Tirbanibulin (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors Almirall S.A.
- 15 Apr 2021 Study design changed to parallel.
- 15 Jan 2019 Status changed from active, no longer recruiting to completed.
- 20 Feb 2018 Results presented in an Athenex media release.